Pacer Advisors’s Avanos Medical AVNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-328,805
Closed -$3.8M 3815
2025
Q3
$3.8M Sell
328,805
-148,738
-31% -$1.74M 0.01% 794
2025
Q2
$5.85M Buy
477,543
+54,931
+13% +$691K 0.01% 640
2025
Q1
$6.06M Buy
+422,612
New +$6.6M 0.01% 587
2023
Q1
Sell
-239,171
Closed -$6.47M 2207
2022
Q4
$6.47M Buy
239,171
+62,617
+35% +$1.53M 0.03% 400
2022
Q3
$3.85M Buy
+176,554
New +$4.61M 0.03% 379
2021
Q2
Sell
-5,120
Closed -$224K 1421
2021
Q1
$224K Sell
5,120
-210
-4% -$9.86K ﹤0.01% 1262
2020
Q4
$245K Sell
5,330
-6,210
-54% -$258K ﹤0.01% 1208
2020
Q3
$383K Buy
+11,540
New +$369K 0.01% 1071
2020
Q1
Sell
-16,279
Closed -$549K 694
2019
Q4
$549K Sell
16,279
-1,240
-7% -$44.9K 0.02% 748
2019
Q3
$656K Sell
17,519
-1,360
-7% -$51.9K 0.01% 938
2019
Q2
$823K Buy
+18,879
New +$808K 0.02% 873
2018
Q4
Sell
-16,723
Closed -$1.15M 572
2018
Q3
$1.15M Buy
16,723
+1,849
+12% +$119K 0.04% 597
2018
Q2
$852K Buy
14,874
+2,215
+17% +$117K 0.04% 706
2018
Q1
$583K Buy
12,659
+1,357
+12% +$64.4K 0.03% 680
2017
Q4
$522K Buy
+11,302
New +$519K 0.04% 686

Other funds holding AVNS

Pacer Advisors's AVNS Position: Q4 2025 in Review

Pacer Advisors sold out of Avanos Medical (AVNS) in Q4 2025, closing a stake of 328,805 shares — an estimated $3.8M sold.

Pacer Advisors first reported a position in AVNS in Q4 2017 and held it in 15 quarters. The position peaked at $6.47M in Q4 2022. 274 funds tracked by Wall St. Rank hold AVNS as of Q4 2025.

  • Pacer Advisors reported no remaining Avanos Medical position as of Q4 2025 after selling out during the quarter.
  • Pacer Advisors sold 328,805 Avanos Medical shares in Q4 2025, an estimated $3.8M.
  • Pacer Advisors first reported a position in Avanos Medical in Q4 2017 and held it in 15 quarters.
  • Pacer Advisors's Avanos Medical position peaked at $6.47M in Q4 2022.
  • 274 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2025.

Based on Pacer Advisors's 13F filing for Q4 2025, filed 4 Feb 2026.